Cargando…
Third booster vaccination and stopping the Omicron, a new variant of concern
The SARS-CoV-2 omicron variant is recent member of variant of concerns that confer neutralizing antibodies and escape immune system due to harboring more than 40 mutations. Current evidences suggest two dosages SARS-CoV-2 vaccine dose not efficient protects against new variants of SARS-CoV-2; howeve...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier España, S.L.U.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259195/ https://www.ncbi.nlm.nih.gov/pubmed/35818430 http://dx.doi.org/10.1016/j.vacun.2022.05.005 |
_version_ | 1784741721374982144 |
---|---|
author | Ghazvini, Kiarash Karbalaei, Mohsen Keikha, Masoud |
author_facet | Ghazvini, Kiarash Karbalaei, Mohsen Keikha, Masoud |
author_sort | Ghazvini, Kiarash |
collection | PubMed |
description | The SARS-CoV-2 omicron variant is recent member of variant of concerns that confer neutralizing antibodies and escape immune system due to harboring more than 40 mutations. Current evidences suggest two dosages SARS-CoV-2 vaccine dose not efficient protects against new variants of SARS-CoV-2; however, recent studies declare that the third booster vaccination can elicit higher antibodies concentration as well as cross-reaction between neutralizing antibodies and new SARS-CoV-2 variants. On the other hand, although a third booster vaccination seems to be benefit in some immunocompromised patients such as recipients of solid-organ transplants or hemodialysis patients, but in other immunosuppressed patients, for instance patients with B cell lymphoproliferative disease partially respond to SARS-CoV-2. Herein, we evaluate the effectiveness of the third booster vaccination against Omicron variant using comprehensive literature review. |
format | Online Article Text |
id | pubmed-9259195 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier España, S.L.U. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92591952022-07-07 Third booster vaccination and stopping the Omicron, a new variant of concern Ghazvini, Kiarash Karbalaei, Mohsen Keikha, Masoud Vacunas Review Article The SARS-CoV-2 omicron variant is recent member of variant of concerns that confer neutralizing antibodies and escape immune system due to harboring more than 40 mutations. Current evidences suggest two dosages SARS-CoV-2 vaccine dose not efficient protects against new variants of SARS-CoV-2; however, recent studies declare that the third booster vaccination can elicit higher antibodies concentration as well as cross-reaction between neutralizing antibodies and new SARS-CoV-2 variants. On the other hand, although a third booster vaccination seems to be benefit in some immunocompromised patients such as recipients of solid-organ transplants or hemodialysis patients, but in other immunosuppressed patients, for instance patients with B cell lymphoproliferative disease partially respond to SARS-CoV-2. Herein, we evaluate the effectiveness of the third booster vaccination against Omicron variant using comprehensive literature review. Elsevier España, S.L.U. 2022 2022-07-07 /pmc/articles/PMC9259195/ /pubmed/35818430 http://dx.doi.org/10.1016/j.vacun.2022.05.005 Text en © 2022 Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Article Ghazvini, Kiarash Karbalaei, Mohsen Keikha, Masoud Third booster vaccination and stopping the Omicron, a new variant of concern |
title | Third booster vaccination and stopping the Omicron, a new variant of concern |
title_full | Third booster vaccination and stopping the Omicron, a new variant of concern |
title_fullStr | Third booster vaccination and stopping the Omicron, a new variant of concern |
title_full_unstemmed | Third booster vaccination and stopping the Omicron, a new variant of concern |
title_short | Third booster vaccination and stopping the Omicron, a new variant of concern |
title_sort | third booster vaccination and stopping the omicron, a new variant of concern |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259195/ https://www.ncbi.nlm.nih.gov/pubmed/35818430 http://dx.doi.org/10.1016/j.vacun.2022.05.005 |
work_keys_str_mv | AT ghazvinikiarash thirdboostervaccinationandstoppingtheomicronanewvariantofconcern AT karbalaeimohsen thirdboostervaccinationandstoppingtheomicronanewvariantofconcern AT keikhamasoud thirdboostervaccinationandstoppingtheomicronanewvariantofconcern |